Arbele Ltd
Arbele is a biotechnology company focused on revolutionizing cancer treatment through innovative immunotherapy solutions. They develop antibody-based biologics targeting gastrointestinal cancers, including stomach, pancreas, colon, bile duct, and liver. Their mission is to accelerate the development of effective treatments for patients by inventing proprietary immunotherapy platforms and advancing precision oncology technologies.
Industries
Nr. of Employees
small (1-50)
Arbele Ltd
Products
CDH17/CD3 bispecific T-cell engager (early clinical)
A CDH17-targeted CD3-engaging bispecific designed to recruit T cells to CDH17-expressing gastrointestinal tumors; advanced into first‑in‑human Phase I clinical evaluation.
CDH17-targeted antibody–drug conjugates (ADC) portfolio
A pipeline of CDH17-targeting ADC candidates derived from an internal monoclonal antibody library, including mono- and biparatopic constructs intended for CDH17-positive tumors at preclinical and early clinical stages.
CAR-T and CAR-NK cell therapy candidates
Non-viral CAR-T and CAR-NK constructs engineered for solid tumor targeting with context‑responsive gene expression and strategies to overcome tumor immunosuppression; programs at discovery and preclinical stages.
CDH17 IHC, blood-based, and POCT diagnostic assays (development)
Diagnostic programs including tissue immunohistochemistry assays, blood-based screening tests for colorectal cancer surveillance, and point-of-care test prototypes for CDH17 detection, progressing from prototyping through clinical studies.
CDH17/CD3 bispecific T-cell engager (early clinical)
A CDH17-targeted CD3-engaging bispecific designed to recruit T cells to CDH17-expressing gastrointestinal tumors; advanced into first‑in‑human Phase I clinical evaluation.
CDH17-targeted antibody–drug conjugates (ADC) portfolio
A pipeline of CDH17-targeting ADC candidates derived from an internal monoclonal antibody library, including mono- and biparatopic constructs intended for CDH17-positive tumors at preclinical and early clinical stages.
CAR-T and CAR-NK cell therapy candidates
Non-viral CAR-T and CAR-NK constructs engineered for solid tumor targeting with context‑responsive gene expression and strategies to overcome tumor immunosuppression; programs at discovery and preclinical stages.
CDH17 IHC, blood-based, and POCT diagnostic assays (development)
Diagnostic programs including tissue immunohistochemistry assays, blood-based screening tests for colorectal cancer surveillance, and point-of-care test prototypes for CDH17 detection, progressing from prototyping through clinical studies.
Services
Drug co-development and strategic collaborations
Collaborative partnerships for co-development of drug candidates across clinical phases, ADC linker/payload development, CAR-T/NK gene-editing and allogeneic approaches, and diagnostics commercialization.
IVD development and companion diagnostic services
Development of tissue IHC assays, blood-based screening tests, and point-of-care diagnostic prototypes through prototyping, clinical studies, and manufacturing readiness.
CMC process development and pilot manufacturing for ADCs
Process development and pilot-scale production support for ADC manufacturing, including tendered pilot batch activities and process optimization.
Management of GLP toxicology and preclinical safety studies
Sourcing and oversight of GLP-compliant repeat-dose toxicology studies to support IND-enabling safety packages.
Drug co-development and strategic collaborations
Collaborative partnerships for co-development of drug candidates across clinical phases, ADC linker/payload development, CAR-T/NK gene-editing and allogeneic approaches, and diagnostics commercialization.
IVD development and companion diagnostic services
Development of tissue IHC assays, blood-based screening tests, and point-of-care diagnostic prototypes through prototyping, clinical studies, and manufacturing readiness.
CMC process development and pilot manufacturing for ADCs
Process development and pilot-scale production support for ADC manufacturing, including tendered pilot batch activities and process optimization.
Management of GLP toxicology and preclinical safety studies
Sourcing and oversight of GLP-compliant repeat-dose toxicology studies to support IND-enabling safety packages.
Expertise Areas
- CDH17-targeted therapeutics and diagnostics
- Multispecific antibody engineering
- Antibody-drug conjugate (ADC) development
- Cell therapy (CAR-T/CAR-NK) development
Key Technologies
- Bispecific and trispecific antibody engineering
- Antibody-drug conjugates (ADC) platforms
- Chimeric antigen receptor (CAR) cell engineering
- Immunohistochemistry (IHC) diagnostics